Oncocyte Corp Stock Today
| OCX Stock | USD 3.70 0.04 1.07% |
PerformanceGood
| Odds Of DistressLow
|
OncoCyte Corp is trading at 3.70 as of the 17th of March 2025; that is 1.07% down since the beginning of the trading day. The stock's open price was 3.74. OncoCyte Corp has less than a 10 % chance of experiencing some financial distress in the next two years of operation and had a good performance during the last 90 days. The performance scores are derived for the period starting the 17th of December 2024 and ending today, the 17th of March 2025. Click here to learn more.
Business Domain Pharmaceuticals, Biotechnology & Life Sciences | IPO Date 4th of January 2016 | Category Healthcare | Classification Health Care |
OncoCyte Corporation, a molecular diagnostics company, researches, develops, and commercializes proprietary laboratory-developed tests for the detection of cancer in the United States and internationally. OncoCyte Corporation was incorporated in 2009 and is based in Irvine, California. The company has 28.6 M outstanding shares of which 319.47 K shares are now shorted by investors with about 3.44 days to cover. More on OncoCyte Corp
Moving against OncoCyte Stock
Follow Valuation Profit Patterns Odds of Bankruptcy
Check how we calculate scores
OncoCyte Stock Highlights
ESG Sustainability
Environmental | Governance | Social |
| CEO | Michael West | ||||
| Business Concentration | Biotechnology, Pharmaceuticals, Biotechnology & Life Sciences, Health Care, NASDAQ Composite, NASDAQ Health Care, Health Care, Biotechnology, Biotechnology, Healthcare (View all Sectors) | ||||
| Average Analyst Recommendation | |||||
Debt LevelsOncoCyte Corp can leverage the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand OncoCyte Corp's financial leverage. It provides some insight into what part of OncoCyte Corp's total assets is financed by creditors.
| |||||
OncoCyte Corp (OCX) is traded on NASDAQ Exchange in USA. It is located in 15 Cushing, Irvine, CA, United States, 92618 and employs 43 people. OncoCyte Corp is listed under Biotechnology category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with a total capitalization of 106.96 M. OncoCyte Corp runs under Biotechnology sector within Health Care industry. The entity has 28.6 M outstanding shares of which 319.47 K shares are now shorted by investors with about 3.44 days to cover.
OncoCyte Corp has about 45.41 M in cash with (23.32 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 0.38.
Check OncoCyte Corp Probability Of Bankruptcy
Ownership AllocationOncoCyte Corp owns a total of 28.6 Million outstanding shares. Over half of OncoCyte Corp's outstanding shares are owned by third-party entities. These third-party entities are typically referred to as corporate investors that secure positions in a given instrument to benefit from reduced trade commissions. Please note that no matter how many assets the company maintains, if the real value of the company is less than the current market value, you may not be able to make money on it.
Check OncoCyte Ownership Details
OncoCyte Stock Institutional Holders
| Instituion | Recorded On | Shares | |
| Two Sigma Securities, Llc | 2024-12-31 | 13.2 K | |
| Ground Swell Capital, Llc | 2024-12-31 | 10.9 K | |
| Tower Research Capital Llc | 2024-12-31 | 4.3 K | |
| Ubs Group Ag | 2024-12-31 | 2.7 K | |
| Lee Danner & Bass Inc | 2024-12-31 | 1.4 K | |
| Bank Of America Corp | 2024-12-31 | 436 | |
| Bryn Mawr Trust Company | 2024-12-31 | 250 | |
| Bnp Paribas Arbitrage, Sa | 2024-12-31 | 208 | |
| Jpmorgan Chase & Co | 2024-12-31 | 195 | |
| Broadwood Capital Inc | 2024-12-31 | 6.2 M | |
| Awm Investment Company Inc | 2024-12-31 | 775.8 K |
OncoCyte Corp Historical Income Statement
OncoCyte Stock Against Markets
OncoCyte Corp Corporate Management
| Andrea James | Chief Officer | Profile | |
| Ekkehard MD | Chief Officer | Profile | |
| Joshua Riggs | Interim Officer | Profile | |
| Tony Kalajian | Senior Vice President Chief Accounting Officer | Profile | |
| Andrew Last | Independent Director | Profile | |
| William Annett | Advisor | Profile |
Additional Tools for OncoCyte Stock Analysis
When running OncoCyte Corp's price analysis, check to measure OncoCyte Corp's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy OncoCyte Corp is operating at the current time. Most of OncoCyte Corp's value examination focuses on studying past and present price action to predict the probability of OncoCyte Corp's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move OncoCyte Corp's price. Additionally, you may evaluate how the addition of OncoCyte Corp to your portfolios can decrease your overall portfolio volatility.